The decreased proteins include proteins with known functions for glioma stemness and migration/invasion like CD9 [23] (Gos, ATO/Gos), Ephrin receptor A2 (EPHA2 [24]; Gos, GANT/Gos) and mesenchymal (i.e., more aggressive) differentiation like FRAS1 related extracellular matrix protein 2 (FREM2 [25]; ATO/Gos). This evidence concerns the gene ECM2 and central nervous system cancer.